| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 01/15/2004 | US20040009968 Indazole compounds useful as protein kinase inhibitors |
| 01/15/2004 | US20040009965 Treating hyperproliferative disorders |
| 01/15/2004 | US20040009961 Composition and therapies for hyperlipidaemia-associated disorders |
| 01/15/2004 | US20040009950 Secreted human proteins |
| 01/15/2004 | US20040009914 Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis |
| 01/15/2004 | US20040009895 Also stimulating interleukin-18 or GM-CSF by administering lactoferrin |
| 01/15/2004 | US20040009595 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| 01/15/2004 | US20040009546 Compositions and methods for inhibiting microbial adhesion |
| 01/15/2004 | US20040009244 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 01/15/2004 | US20040009216 Administering liposomes comprising phospholipids and an aqueous layer, said liposomes having specified average diameter; treating various cardiovascular disorders, reducing cholesterol |
| 01/15/2004 | US20040009191 Inactivated virulence genes |
| 01/15/2004 | US20040009187 Rotavirus subunit vaccine |
| 01/15/2004 | US20040009169 Administration of agents for the treatment of inflammation |
| 01/15/2004 | US20040009167 Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain; use in preventing or treating a pathogen infection in a cell or organism |
| 01/15/2004 | CA2492535A1 New quinuclidine amide derivatives |
| 01/15/2004 | CA2492121A1 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| 01/15/2004 | CA2491998A1 Azabicyclo derivatives as muscarinic receptor antagonists |
| 01/15/2004 | CA2491994A1 Modulators of the glucocorticoid receptor |
| 01/15/2004 | CA2491710A1 Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
| 01/15/2004 | CA2491685A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-prolpylene glycol |
| 01/15/2004 | CA2491682A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | CA2491478A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | CA2491464A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives |
| 01/15/2004 | CA2491455A1 Novel use of imidazotriazinones |
| 01/15/2004 | CA2491127A1 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 01/15/2004 | CA2490714A1 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | CA2490463A1 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough |
| 01/15/2004 | CA2490147A1 Liquid dosage forms of non-enterically coated proton pump inhibitors |
| 01/15/2004 | CA2490145A1 Liquid dosage forms of proton pump inhibitors |
| 01/15/2004 | CA2490142A1 Liquid dosage forms of proton pump inhibitors |
| 01/15/2004 | CA2490097A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| 01/15/2004 | CA2489402A1 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 01/15/2004 | CA2489398A1 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| 01/15/2004 | CA2489251A1 Quinazoline derivatives |
| 01/15/2004 | CA2488736A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 01/14/2004 | EP1380562A1 Carboxylic acid derivative and salt thereof |
| 01/14/2004 | EP1380307A1 Tissue fibrosis inhibitors |
| 01/14/2004 | EP1380303A1 Combination therapy to treat hepatitis B virus |
| 01/14/2004 | EP1380296A1 Hsp inductor |
| 01/14/2004 | EP1380294A1 Preventive/remedial agent for inflammatory disease in oral-cavity mucosa and the like |
| 01/14/2004 | EP1379695A2 New polynucleotides and polypeptides of the ifnalpha-21 gene |
| 01/14/2004 | EP1379694A2 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 01/14/2004 | EP1379679A2 Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof |
| 01/14/2004 | EP1379672A2 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) |
| 01/14/2004 | EP1379656A2 G-protein coupled receptor molecules and uses thereof |
| 01/14/2004 | EP1379654A2 Intracellular signaling molecules |
| 01/14/2004 | EP1379652A2 Human nucleic acid molecules and polypeptides encoding a human ion channel expressed in spinal cord and brain |
| 01/14/2004 | EP1379628A2 Kinases and phosphatases sequences, and use thereof |
| 01/14/2004 | EP1379626A2 A method for differentiating stem cells into insulin-producing cells |
| 01/14/2004 | EP1379557A2 Use of cd25 binding molecules in steroid-resistant patients |
| 01/14/2004 | EP1379542A2 Treatment of tumours |
| 01/14/2004 | EP1379533A2 Novel cyclo azaphospha hydrocarbons |
| 01/14/2004 | EP1379528A1 Pyrazolopyrimidines as therapeutic agents |
| 01/14/2004 | EP1379522A1 DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I |
| 01/14/2004 | EP1379519A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379518A2 Process for purifying 6-methoxy omeprazole |
| 01/14/2004 | EP1379515A1 Lipid lowering biphenylcarboxamides |
| 01/14/2004 | EP1379507A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS |
| 01/14/2004 | EP1379504A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors |
| 01/14/2004 | EP1379503A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379495A2 Ligands of the alpha-v-beta 6 integrin |
| 01/14/2004 | EP1379494A1 Fused bicyclic or tricyclic amino acids |
| 01/14/2004 | EP1379265A2 Short bioactive peptides and methods for their use |
| 01/14/2004 | EP1379261A2 Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
| 01/14/2004 | EP1379257A2 Prodrugs of anticancer agents employing substituted aromatic acids |
| 01/14/2004 | EP1379254A1 Use of bile acid or bile salt fatty acid conjugates |
| 01/14/2004 | EP1379242A1 Method for treatment of cancer and compositions for use therein |
| 01/14/2004 | EP1379235A2 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 01/14/2004 | EP1379230A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
| 01/14/2004 | EP1379224A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 01/14/2004 | EP1379130A2 Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease |
| 01/14/2004 | EP1379125A1 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 01/14/2004 | EP1124534B1 Expandable gastroretentive therapeutical system with prolonged stomach retention time |
| 01/14/2004 | EP1112265B1 2-arylalkylthio -imidazoles, 2-arylalkenyl -thio -imidazoles and 2-arylalkinyl -thio -imidazoles as anti -inflammatory substances and substances inhibiting the release of cytokine |
| 01/14/2004 | EP0934074B1 Use of ginkgo biloba flavonoidic extract comprising up to 1% of terpenes, associated with ceramides, for oral hygiene and compositions containing such extract |
| 01/14/2004 | CN1468305A Modulation of the transcription of pro-inflammatory gene products |
| 01/14/2004 | CN1468296A Use of essential oils for combating gi tract infection by helicobacter-like organisms |
| 01/14/2004 | CN1468258A Glucagon-like peptide-1 analogs |
| 01/14/2004 | CN1468249A Methods and compositions for treating flaviviruses and pestiviruses |
| 01/14/2004 | CN1468236A Novel anticholinergic agents that can be used as medicaments and method for the production thereof |
| 01/14/2004 | CN1468226A Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 01/14/2004 | CN1468220A New piperidine derivatives |
| 01/14/2004 | CN1468219A Piperidine derivatives and drugs containing these derivatives as the active ingredient |
| 01/14/2004 | CN1468214A Novel derivatives of aminocyclohexane |
| 01/14/2004 | CN1468123A Method and composition for altering a b cell mediated pathology |
| 01/14/2004 | CN1468105A Use of probiotic lactic acid bacteria for balancing the skin's immune system |
| 01/14/2004 | CN1468060A Oil/fat composition |
| 01/14/2004 | CN1467218A Application of misplaced dichain oligonucleotide in preparing medicines for treating human liver cancer |
| 01/14/2004 | CN1467207A Method for preparing solid optical pure neutral S- (-) - and (R) - (+) -Omeprazole |
| 01/14/2004 | CN1466990A Health food for protecting liver and adjusting blood fat and method for preparing the same |
| 01/14/2004 | CN1466985A Medicine for treating tummy bug |
| 01/14/2004 | CN1466984A Medicine for treating hepatitis |
| 01/14/2004 | CN1466983A Matrimony vine royal jelly capsule and method for preparing the same |
| 01/14/2004 | CN1466982A Chinese herbal medicine hepatocirrhosis reversion preparation |
| 01/14/2004 | CN1466977A Kidney tonifying and bowel relaxing capsule |
| 01/14/2004 | CN1466970A Nanometer oral liquid of six drugs containing rehmanniae |
| 01/14/2004 | CN1466965A Medicine for treating toothache |
| 01/14/2004 | CN1466959A Medicine for treating toothache and peridontoclasia |
| 01/14/2004 | CN1466958A Anti-consenescence anti-fatigue health-product containing pure plant extracts |
| 01/14/2004 | CN1466955A Composite biological active capsule and method for preparing the same |